Serum periostin and eotaxin-2 as promising biomarkers in asthmatic smokers

Le résumé fourni par la source

Serum periostin and eotaxin-2 as promising biomarkers in asthmatic smokers. Background: Smoking influence many changes in asthmatic airway inflammation by stimulating the production of certain cytokines. Serum periostin and eotaxin-2 in asthmatic patients are affected by smoking. Objectives: The purpose of this study was to study serum periostin and eotaxin-2 level in asthmatic smokers. Patients and methods: The present observational, cross sectional study was conducted at Chest department in Assiut university hospital, during the period from August 2018 to January 2020. Hundred and seventeen asthmatic patients (42 smokers, 30 ex-smokers and 45 non-smokers) were studied for serum periostin and eotaxin-2 (ELISA). The effects of smoking status and inflammatory biomarkers including sputum eosinophilic and neutrophilic count on serum level of periostin and eotaxin-2 in asthmatic patients were analysed. Results: Serum periostin was significantly higher in non-smokers in comparison to smokers and ex-smokers. However, serum eotaxin-2 was significantly higher among smokers in comparison to non-smokers and ex-smokers. Serum periostin had negative correlation with smoking index, and positive correlation with eosinophils count, while serum eotaxin-2 had positive correlation with smoking index, eosinophilic and neutrophilic count in sputum. Conclusion: Asthmatic smokers represent a distinct phenotype of the disease. This inflammatory phenotype seen in smokers with asthma showed increased serum eotaxin-2 and low serum periostin.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.